Showing results (151-160 of 538) with videos related to
Sort By:
Pageof 54
Genes|March 29, 2023
Personalized Systemic Therapies in Hereditary Cancer SyndromesLuciana Mastrodomenico, Claudia Piombino, Beatrice Riccò, et al.Journal of Separation Science|October 30, 2008
Dielectric cell separation of fine needle aspirates from tumor xenograftsMassimo Cristofanilli, Savitri Krishnamurthy, Chandra M Das, et al.Oncotarget|January 17, 2019
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancerDaphne Brisard, Frank Eckerdt, Lindsey A Marsh, et al.Clinical Breast Cancer|July 19, 2014
Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcomeJennifer M Matro, Tianyu Li, Massimo Cristofanilli, et al.Cancer Chemotherapy and Pharmacology|September 30, 2005
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancerSilwan Chedid, Edgardo Rivera, Debbie K Frye, et al.Cancer Treatment Reviews|July 28, 2017
Fertility and pregnancy issues in BRCA-mutated breast cancer patientsMatteo Lambertini, Oranite Goldrat, Angela Toss, et al.Breast Cancer Research and Treatment|September 23, 2016
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancerStephen Johnston, Mark Basik, Roberto Hegg, et al.Breast Cancer Research and Treatment|June 1, 2018
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapySarika Jain, Ami N Shah, Cesar A Santa-Maria, et al.Breast Cancer Research and Treatment|March 11, 2008
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancerJulie E Lang, Kailash Mosalpuria, Massimo Cristofanilli, et al.BMC Cancer|July 27, 2016
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patientsShaohua Zhang, Lei Li, Tao Wang, et al.Pageof 54